Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Circ Res. Author manuscript; available in PMC 2013 August 31.
Published in final edited form as:
PMCID: PMC3462817

Metabolic remodeling in the hypertrophic heart: Fuel for thought

When it comes to fuel for energy production it is commonly accepted that the heart is an omnivore, capable of oxidizing a wide range of carbon substrates, and that this metabolic plasticity is necessary in order to maintain a high and variable workload in the midst of an ever changing hormonal and nutritional state.1 It is also widely appreciated that shifts in substrate utilization in the heart occur in response to chronic metabolic and hemodynamic stresses.25 What is less clear, however, is whether such chronic metabolic shifts should be considered a cause or consequence in the pathogenesis of contractile dysfunction. In the case of diabetes mellitus, the heart exhibits an increased dependence on fatty acids for oxidative energy production, and this increase in lipid metabolism has been proposed to significantly contribute towards the etiology of impaired cardiac function.6 Similarly, increased rates of fatty acid oxidation immediately following an ischemic event have been implicated in exacerbation of reperfusion injury.7 However, in both of these pathophysiological settings compelling data to support a direct causal relationship between contractile abnormalities and metabolic dysregulation remains elusive.

In response to pressure overload-induced cardiac hypertrophy, the heart reverts more towards a fetal-like metabolic profile, indicative of a decrease in fatty acid oxidation (concomitant with an increased reliance on carbohydrates for oxidative energy metabolism).3 It has been suggested that this substrate shift, which is associated with reactivation of other fetal-like hallmarks (e.g., myosin heavy chain isoform switching), contributes towards the progression to overt contractile failure.8 Dietary, pharmacologic, and genetic strategies have been employed previously, in attempts to provide insight regarding the impact that substrate shifts have on pressure overload-induced remodeling; however, mixed results have been reported. For example, high fat feeding attenuates hypertension-induced myocardial remodeling and contractile dysfunction in rats.9 Similar findings have been reported in animal models of heart failure, which are associated with restoration of fatty acid oxidative capacity.10 Conversely, induction of fatty acid metabolism enzymes through use of PPARα agonists prevents substrate switching and augments pressure overload-induced contractile dysfunction.11 On the other hand, both dietary and pharmacological interventions have significant systemic effects, and PPARα activation influences processes beyond fatty acid oxidation. These experimental shortcomings, in addition to the tight coupling between cardiac work and oxidative metabolism, have made demonstration of a direct causal relationship between shifts in substrate utilization and contractile dysfunction a significant challenge.

In the current issue of Circulation Research, Kolwicz and colleagues utilized a novel genetic approach designed to establish a more definitive relationship between the metabolic shifts with contractile dysfunction observed in pressure overload-induced hypertrophy. The investigators hypothesized that heart-specific genetic ablation of acetyl-CoA carboxylase 2 (ACC2H−/−), which generates malonyl-CoA (a critical inhibitor of mitochondrial fatty acid uptake), would prevent the characteristic substrate switching during pressure overload-induced hypertrophy, concomitant with the other aspects of remodeling (inclusive of contractile function). Consistent with this hypothesis, using ex vivo assessment of substrate utilization Kolwicz et al revealed the predicted transverse aortic constriction (TAC)-induced alterations in substrate reliance (i.e., decreased fatty acid oxidation and increased glucose oxidation), in wild type hearts, but these changes were absent in the ACC2H−/−, hearts. The lack of substrate switching observed in ACC2H−/− hearts was associated with marked attenuations in TAC-induced hypertrophic growth (cardiomyocyte size, heart weight, and molecular markers [bnp mRNA]), fibrosis, and contractile dysfunction. Collectively, these observations are consistent with the concept that perturbations in cardiac metabolism play a causal role in the remodeling of the heart in response to pressure overload.

Metabolic dysregulation as a direct link to the development of cardiac dysfunction has gained increased acceptance over the last several decades, a concept that is strengthened further in the study by Kolwicz et al. However, despite the development of more refined techniques for measuring substrate utilization, as well as increasingly sophisticated genetic approaches for manipulating key regulatory enzymes, establishing the molecular underpinnings by which shifts in cardiac metabolism casually influence remodeling remains elusive. A classical perspective has centered on energetics, based on the relatively simple viewpoint that metabolic dysregulation leads to impaired energy transfer resulting in impaired contractile function.12 Given that fatty acids act as a primary source of ATP for the contracting adult heart, multiple laboratories have speculated that diminished fatty acid oxidative capacity negatively impacts cardiac function through energy starvation. Consistent with this idea, Kolwicz et al highlighted a modest decrease in the phosphocreatine (PCr)-to-ATP ratio in wild-type, but not ACC2H−/−, hearts following TAC. While it is tempting to link the development of metabolic inflexibility to impaired bioenergetics, it should be noted that at least in overt heart failure the decline in PCr/ATP ratio appears to be due to an impaired creatine kinase flux and a decrease in total tissue creatine content.13 Clearly an impaired energetic reserve has important implications in the failing heart; however a strong case linking dysregulation in substrate ultilization and decreased PCr/ATP remains lacking.

What is becoming increasingly apparent is that metabolic intermediates in both glucose and lipid metabolism can have potent effects on cardiomyocyte function, and that the changes in these so-called metabolic signals are more likely to contribute to pathophysiological changes associated with metabolic inflexibility than subtle changes in energetics. For example, it is well established that other pathways of glucose metabolism, such as the pentose phosphate pathway, diacylglycerol pathway and the hexosamine biosynthesis pathway (HBP), while not consuming the majority of glucose entering the cell, can significantly affect cellular function. The HBP has long been described as a “nutrient sensing pathway” and while its role in mediating metabolic signaling in the heart remains relatively understudied it has garnered increasing interest because the HBP plays a key role in regulating the modification of Ser/Thr residues of numerous nuclear and cytoplasmic proteins by the O-linked attachment of a single monosaccharide, N-acetyl-D-glucosamine, more commonly known as O-GlcNAc.1416 In the context of the heart, increases in O-GlcNAc levels have been implicated in mediating adverse effects of diabetes, and acute activation of O-GlcNAc levels have also been shown to be cardioprotective.1719 With regard to cardiac hypertrophy a number of studies have demonstrated that pressure-overload induced hypertrophy appears to increase flux through the HBP (consistent with increased glucose utilization), and further that cardiac specific genetic ablation of O-GlcNAc transferase, which catalyzes O-GlcNAc synthesis, prevents TAC-induced hypertrophy.20, 21 Interestingly, it has also been recently reported that O-GlcNAc synthesis is required for activation of the transcriptional reprogramming that occurs at the onset and progression of cardiac hypertrophy.22

It should also be noted that augmenting glucose metabolism by increasing GLUT1 expression in the heart, was found to attenuate TAC induced remodeling; however the impact of increased GLUT1 on the HBP or other accessory pathways of glucose metabolism is not known.23 Indeed it is perhaps somewhat of a paradox that augmenting glucose use with GLUT1 overexpression an increasing fatty acid use in the ACC2H−/− model both attenuated the response to TAC. This perhaps reinforces the notion that other metabolic signaling pathways may be of importance. This might include lipid metabolism pathways. Decreased fatty acid oxidation capacity, in the face of sustained or elevated fatty acid availability, would be predicted to facilitate the channeling of fatty acyl groups into non-oxidative pathways.4, 24 Many of these pathways, including DAG and phospholipid biosynthesis, play critical roles in cellular signaling. Furthermore, comparable to the glucose-derived post translational modification discussed above (i.e., O-GlcNAcylation), direct palmitoylation of several proteins critical to cardiomyocyte function have been demonstrated.25

In summary, through the use of a novel mouse model of augmented fatty acid oxidation (i.e., ACC2H−/−), Kolwicz et al have established a causal relationship between pressure overload-induced alterations in cardiac metabolism and remodeling. These exciting findings open the door to several unanswered questions, particularly in relation to the mechanism(s) by which shifts in metabolism act in a signaling manner to facilitate remodeling of the myocardium in response to stresses (Figure 1). Undoubtedly, the findings fuel the concept that modulating metabolism in a targeted fashion is potentially a viable therapeutic strategy in the treatment of hypertrophic cardiomyopathy.

Figure 1
Hypothetical model by which metabolic signals potentially modulate cardiac remodeling


This work was supported by the National Heart, Lung, and Blood Institute (MEY: HL-074259 and HL-106199; JCC HL101192 and HL110366).


Disclosures None.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


1. Taegtmeyer H. Metabolism--the lost child of cardiology. J Am Coll Cardiol. 2000;36:1386–1388. [PubMed]
2. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial Fatty Acid metabolism in health and disease. Physiol Rev. 2010;90(1):207–258. [PubMed]
3. Allard M, Schonekess B, Henning S, English D, Lopaschuk G. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol. 1994;267:H742–H750. [PubMed]
4. Abel E, Litwin S, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008;88:389–419. [PMC free article] [PubMed]
5. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation. 2002;105(14):1727–1733. [PubMed]
6. Larsen TS, Aasum E. Metabolic (in)flexibility of the diabetic heart. Cardiovasc Drugs Ther. 2008;22(2):91–95. [PubMed]
7. Lopaschuk GD, Wambolt RB, Barr RL. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther. 1993;264(1):135–144. [PubMed]
8. Taegtmeyer H, Sen S, Vela D. Return to the fetal gene program: a suggested metabolic link to gene expression in the heart. Ann N Y Acad Sci. 2010;1188:191–198. [PMC free article] [PubMed]
9. Okere IC, Young ME, McElfresh TA, Chess DJ, Sharov VG, Sabbah HN, Hoit BD, Ernsberger P, Chandler MP, Stanley WC. Low carbohydrate/high-fat diet attenuates cardiac hypertrophy, remodeling, and altered gene expression in hypertension. Hypertension. 2006;48(6):1116–1123. [PubMed]
10. Berthiaume JM, Young ME, Chen X, McElfresh TA, Yu X, Chandler MP. Normalizing the metabolic phenotype after myocardial infarction: Impact of subchronic high fat feeding. J Mol Cell Cardiol. 2012;53(1):125–133. [PMC free article] [PubMed]
11. Young M, Laws F, Goodwin G, Taegtmeyer H. Reactivation of peroxisome proliferator-activated receptor {alpha} is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem. 2001;276:44390–44395. [PubMed]
12. Neubauer S. The failing heart--an engine out of fuel. N Engl J Med. 2007;356(11):1140–1151. [PubMed]
13. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res. 2009;81(3):412–419. [PMC free article] [PubMed]
14. McClain DA. Hexosamines as mediators of nutrient sensing and regulation in diabetes. J Diabetes Complications. 2002;16(1):72–80. [PubMed]
15. Hanover JA, Krause MW, Love DC. The hexosamine signaling pathway: OGlcNAc cycling in feast or famine. Biochim Biophys Acta. 2010;1800(2):80–95. [PMC free article] [PubMed]
16. Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. Cross Talk Between OGlcNAcylation and Phosphorylation: Roles in Signaling, Transcription, and Chronic Disease. Annu Rev Biochem. 2011;80:825–858. [PMC free article] [PubMed]
17. Darley-Usmar VM, Ball LE, Chatham JC. Protein O-linked beta-N-acetylglucosamine: a novel effector of cardiomyocyte metabolism and function. J Mol Cell Cardiol. 2012;52(3):538–549. [PubMed]
18. Chatham JC, Marchase RB. The role of protein O-linked beta-N-acetylglucosamine in mediating cardiac stress responses. Biochim Biophys Acta. 2010;1800(2):57–66. [PMC free article] [PubMed]
19. Porter K, Medford HM, McIntosh CM, Marsh SA. Cardioprotection requires flipping the 'posttranslational modification' switch. Life Sci. 2012;90(3–4):89–98. [PubMed]
20. Young ME, Yan J, Razeghi P, Cooksey RC, Guthrie PH, Stepkowski SM, McClain DA, Tian R, Taegtmeyer H. Proposed regulation of gene expression by glucose in rodent heart. Gene Regul Syst Bio. 2007;1:251–262. [PMC free article] [PubMed]
21. Watson LJ, Facundo HT, Ngoh GA, Ameen M, Brainard RE, Lemma KM, Long BW, Prabhu SD, Xuan YT, Jones SP. O-linked beta-N-acetylglucosamine transferase is indispensable in the failing heart. Proc Natl Acad Sci U S A. 2010;107(41):17797–17802. [PubMed]
22. Facundo HT, Brainard RE, Watson LJ, Ngoh GA, Hamid T, Prabhu SD, Jones SP. O-GlcNAc Signaling is Essential for NFAT-Mediated Transcriptional Reprogramming During Cardiomyocyte Hypertrophy. Am J Physiol Heart Circ Physiol. 2012 [PubMed]
23. Liao R, Jain M, Cui L, D'Agostino J, Aiello F, Luptak I, Ngoy S, Mortensen RM, Tian R. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation. 2002;106(16):2125–2131. [PubMed]
24. Young M, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: Potential Mechanisms. Circulation. 2002;105:1861–1870. [PubMed]
25. Chien AJ, Hosey MM. Post-translational modifications of beta subunits of voltage-dependent calcium channels. J Bioenerg Biomembr. 1998;30(4):377–386. [PubMed]